Standard BioTools/$LAB

1D1W1MYTD1Y5YMAX

About Standard BioTools

Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
Ticker
$LAB
Sector
Health
Primary listing
NASDAQ
Employees
387
Headquarters
Boston, United States
Website
www.standardbio.com

LAB Metrics

BasicAdvanced
$302M
3.51
$0.22
1.40
-

What the Analysts think about LAB

Analyst ratings (Buy, Hold, Sell) for Standard BioTools stock.
Analyst projections of the future price of Standard BioTools stock.

Bulls say / Bears say

The planned all-stock merger with Treeline would give investors exposure to three oncology programmes already in Phase 1, a fourth expected to enter the clinic in 2026, and interim data readouts from 2027. That offers a higher-upside, drug-development catalyst than Standard BioTools’ shrinking tools business alone. (GlobeNewswire)
LAB had $541.1 million in cash, cash equivalents and investments at the end of June, strengthened by the SomaScan sale and a $30 million Illumina payment. This gives the business and the proposed combination substantial financial capacity without an immediate need for new funding. (GlobeNewswire, BioSpace)
Cost-cutting is improving the underlying earnings trend: second-quarter adjusted EBITDA loss narrowed 84% year on year to $2.5 million, while non-GAAP operating expenses fell 50%. That supports management’s stated path towards positive adjusted EBITDA as the transition progresses. (BioSpace)
The core tools business is losing momentum. Second-quarter revenue fell 7.6% year on year to $20.1 million, with consumables, instruments and services all lower, and management withdrew its full-year revenue outlook. (BioSpace)
Existing LAB shareholders are expected to own only about 16% of the combined company, versus roughly 84% for Treeline shareholders. This means investors are accepting substantial dilution and shifting from a life-science-tools holding into a predominantly drug-development company. (StockTitan)
The business remains loss-making despite the adjusted EBITDA improvement: second-quarter net loss from continuing operations was $21.5 million, including $14.7 million of transaction costs and $2.8 million of restructuring charges. Continued deal-related spending makes the route to sustainable cash profitability uncertain. (BioSpace)
Data summarised monthly by Lightyear AI. Last updated on 19 Sept 2026.

LAB Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

LAB Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing LAB

AllUSDEURGBP
Funds
Fund name
Fund size
$LAB weighting
iShares Healthcare Innovation$HEAL
$1.4B0.02%
iShares Healthcare Innovation€2B78
€1.2B0.02%
iShares Healthcare Innovation£DRDR
£1B0.02%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.